Exelixis Inc (NAS:EXEL)
$ 20.82 -0.41 (-1.93%) Market Cap: 6.06 Bil Enterprise Value: 5.44 Bil PE Ratio: 32.38 PB Ratio: 2.89 GF Score: 92/100

Exelixis Inc at Bank of America Global Healthcare Conference (Virtual) Transcript

Sep 15, 2021 / 04:35PM GMT
Release Date Price: $20.47 (+1.69%)
Jason Gerberry
BofA Global Research - Analyst

(technical difficulty) biotech analyst at Bank of America. I am pleased to be introducing our next company presenter Exelixis' CEO, Mike Morrissey. Exelixis is a commercial-stage oncology company with some interesting assets in the early-stage pipeline, so a lot to talk about. The Company is in the process of launching a new indication for CABOMETYX that's been doing, particularly, well in the marketplace. So that seems like a logical first place to start. So before we get into that, Mike, first off, thanks for joining us.

Mike Morrissey
Exelixis, Inc. - President & CEO

You bet. Great to be here. Thanks again for the opportunity to chat online. Looking forward to doing this live at some point in time in the near future. Before I begin, let me just remind everybody I'll be making forward-looking statements. So please see our SEC filings for a description of the risks that we face in our business.

Jason Gerberry
BofA Global Research - Analyst

Well, fingers crossed,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot